schliessen

Filtern

 

Bibliotheken

核苷(酸)类药物应答不佳的慢性乙型肝炎患者优化治疗过程中血清IL-21的动态变化及意义

目的:通过检测核苷(酸)类似物治疗应答不佳慢性乙型肝炎患者在优化治疗过程中血清IL-21表达水平,探讨血清IL-21水平的动态变化与患者对抗病毒应答的相关性。方法检测25例核苷(酸)类似物治疗应答不佳的慢性乙型肝炎患者在接受优化的核苷(酸)类似物抗病毒治疗基线、12周、24周、36周、52周、64周、76周、88周和104周的血清并检测IL-21水平、HBV DNA定量、HBsAg、HBsAb、HBeAg、HBeAb和肝功能等相关指标,分析这些指标的动态变化及其之间的相关性;另选取15例HBV携带者、15例健康志愿者做对照。结果核苷(酸)类似物治疗应答不佳的慢性乙型肝炎患者优化治疗基线血清IL... Full description

Journal Title: 中华实验和临床感染病杂志(电子版) 2016, Vol.10(2), pp.140-145
Main Author: 闫改勤
Other Authors: 纪世博 , 刘顺爱 , 欧蔚妮 , 赵莹莹 , 马艳华 , 成军 , 邢卉春
Format: Electronic Article Electronic Article
Language: chi
Subjects:
Quelle: China Online Journals (Wanfang)
ID: ISSN: 1674-1358
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: wanfang_jourzhsyhlcgrbzz201602003
title: 核苷(酸)类药物应答不佳的慢性乙型肝炎患者优化治疗过程中血清IL-21的动态变化及意义
format: Article
creator:
  • 闫改勤
  • 纪世博
  • 刘顺爱
  • 欧蔚妮
  • 赵莹莹
  • 马艳华
  • 成军
  • 邢卉春
subjects:
  • 肝炎病毒,乙型
  • 肝炎,乙型,慢性
  • 白细胞介素21
  • Hepatitis B Virus
  • Chronic Hepatitis B
  • Interleukin-21
ispartof: 中华实验和临床感染病杂志(电子版), 2016, Vol.10(2), pp.140-145
description: 目的:通过检测核苷(酸)类似物治疗应答不佳慢性乙型肝炎患者在优化治疗过程中血清IL-21表达水平,探讨血清IL-21水平的动态变化与患者对抗病毒应答的相关性。方法检测25例核苷(酸)类似物治疗应答不佳的慢性乙型肝炎患者在接受优化的核苷(酸)类似物抗病毒治疗基线、12周、24周、36周、52周、64周、76周、88周和104周的血清并检测IL-21水平、HBV DNA定量、HBsAg、HBsAb、HBeAg、HBeAb和肝功能等相关指标,分析这些指标的动态变化及其之间的相关性;另选取15例HBV携带者、15例健康志愿者做对照。结果核苷(酸)类似物治疗应答不佳的慢性乙型肝炎患者优化治疗基线血清IL-21水平与无症状携带者血清IL-21水平差异无统计学意义,但均显著高于健康对照组(P =0.000、0.003);核苷(酸)类似物应答不佳的慢性乙型肝炎患者在优化治疗过程中血清HBV DNA、HBsAg、HBeAg、HBeAb均呈下降趋势,且HBV DNA水平及HBsAg浓度于治疗12周内下降速度最快,HBsAg浓度降低速度随治疗时间延长逐渐减慢。基线IL-21水平与优化治疗12~24周时的病毒量变化对数值存在中等强度的负相关性(r =-0.55、P =0.015),36周时IL-21水平与36~52周病毒量变化存在中等强度的负相关性(r =-0.62、P =0.001)。核苷(酸)类药物优化治疗过程中患者血清IL-21浓度呈现先升高后下降的趋势,峰值浓度在36周,为66.41 pg/ml,显著高于基线IL-21浓度(P =0.001),治疗至88周及104周时患者血清IL-21水平恢复到基线状态。结论乙型肝炎病毒感染的患者血清IL-21浓度升高,优化核苷(酸)类抗病毒治疗后,慢性乙型肝炎患者血清IL-21水平呈现一过性升高,峰值与HBV DNA的抑制及HBsAg、HBeAg等变化有一定的相关性。
language: chi
source: China Online Journals (Wanfang)
identifier: ISSN: 1674-1358
fulltext: no_fulltext
issn:
  • 1674-1358
  • 16741358
url: Link


@attributes
ID295921196
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordidzhsyhlcgrbzz201602003
sourceidwanfang_jour
recordidTN_wanfang_jourzhsyhlcgrbzz201602003
sourcesystemOther
display
typearticle
title核苷(酸)类药物应答不佳的慢性乙型肝炎患者优化治疗过程中血清IL-21的动态变化及意义
creator
0闫改勤 ; 纪世博 ; 刘顺爱 ; 欧蔚妮 ; 赵莹莹 ; 马艳华 ; 成军 ; 邢卉春
1Yan Gaiqin ; Ji Shibo ; Liu Shun ai ; Ou Weini ; Zhao Yingying ; Ma Yanhua ; Cheng Jun ; Xing Huichun
identifierISSN: 1674-1358
subject肝炎病毒,乙型 ; 肝炎,乙型,慢性 ; 白细胞介素21 ; Hepatitis B Virus ; Chronic Hepatitis B ; Interleukin-21
description
0目的:通过检测核苷(酸)类似物治疗应答不佳慢性乙型肝炎患者在优化治疗过程中血清IL-21表达水平,探讨血清IL-21水平的动态变化与患者对抗病毒应答的相关性。方法检测25例核苷(酸)类似物治疗应答不佳的慢性乙型肝炎患者在接受优化的核苷(酸)类似物抗病毒治疗基线、12周、24周、36周、52周、64周、76周、88周和104周的血清并检测IL-21水平、HBV DNA定量、HBsAg、HBsAb、HBeAg、HBeAb和肝功能等相关指标,分析这些指标的动态变化及其之间的相关性;另选取15例HBV携带者、15例健康志愿者做对照。结果核苷(酸)类似物治疗应答不佳的慢性乙型肝炎患者优化治疗基线血清IL-21水平与无症状携带者血清IL-21水平差异无统计学意义,但均显著高于健康对照组(P =0.000、0.003);核苷(酸)类似物应答不佳的慢性乙型肝炎患者在优化治疗过程中血清HBV DNA、HBsAg、HBeAg、HBeAb均呈下降趋势,且HBV DNA水平及HBsAg浓度于治疗12周内下降速度最快,HBsAg浓度降低速度随治疗时间延长逐渐减慢。基线IL-21水平与优化治疗12~24周时的病毒量变化对数值存在中等强度的负相关性(r =-0.55、P =0.015),36周时IL-21水平与36~52周病毒量变化存在中等强度的负相关性(r =-0.62、P =0.001)。核苷(酸)类药物优化治疗过程中患者血清IL-21浓度呈现先升高后下降的趋势,峰值浓度在36周,为66.41 pg/ml,显著高于基线IL-21浓度(P =0.001),治疗至88周及104周时患者血清IL-21水平恢复到基线状态。结论乙型肝炎病毒感染的患者血清IL-21浓度升高,优化核苷(酸)类抗病毒治疗后,慢性乙型肝炎患者血清IL-21水平呈现一过性升高,峰值与HBV DNA的抑制及HBsAg、HBeAg等变化有一定的相关性。
1Funding organization: 国家科技重大专项课题项目(No.2014ZX10005001) ; 国家自然科学基金项目(No.81201160) ; 北京市中医药科技项目(No. JJ2014-25) ; 国家“十二五”传染病重大专项(2012ZX10002003)
2Objective To investigate of the levels of serum interleukin-21 (IL-21) in the optimally treated chronic hepatitis B (CHB) patients with poor response to nucleos(t)ide analogue drugs to investigate the relationship between the the serum IL-21 levels, the dynamic changes and patients’ viral response to antiviral therapy. Methods The serum of a total of 25 CHB patients with a poor response to nucleos(t) ide analogue antiviral therapy was detached before and after optimally treated for 12, 24, 36, 52, 64, 76, 88 and 104 weeks, and the levels of IL-21, HBsAg, HBsAb, HBeAg, HBeAb, HBV DNA load and the liver function were dedected, respectively. And then the dynamic changes of these indicators and the correlation were analyzed. Fifteen cases of hepatitis B virus carriers and 15 cases of healthy volunteers were selected as controls. Results There was no significant differences between the levels of the baseline IL-21 of the chronic hepatitis B patients poorly respond to nucleos(t)ide analogue antiviral therapy and the hepatitis B virus carriers, but they all significantly higher than the level of serum IL-21 concentration of the healthy people (P < 0.05). During the optimal therapy of the chronic hepatitis B patients poorly respond to nucleos(t) ide analogue antiviral therapy, the level of the serum HBV DNA, HBsAg, HBeAg and HBeAb all declined, and a rapid decline of HBV DNA during the first 12 weeks of treatment was observed, and the pace of the reduction of HBsAg slowed down with time. There was a moderate negative correlation between the IL-21 concentration of baseline and the logarithmic change of HBV load from 12 weeks to 24 weeks after treatment (r =-0.55, P < 0.05). A moderate negative correlation between the IL-21 concentration at week 36 and the decline of HBV load from week 36 to week 52 was also obversed (r =-0.62, P < 0.01). And the levels of IL-21 of the patients with CHB during treatment with nucleos(t)ide analogues increased at first and then declined and the peak concentration was 66.41 pg/ml, which came around at week 36 and was significantly higher than the baseline (P < 0.05), but at the 88th week and 104th week, the IL-21 declined to the levels that showed no significant differences compared with the baseline. Conclusions The levels of serum IL-21 increased in the patients with HBV infection, and after the optimal antiviral treatment with nucleos(t)ide analogue drugs, the levels of serum IL-21 of patients with CHB increased transiently, and some relevance were observed between the supression of HBV DNA, as well as the changes of the HBsAg, HBeAg and the peek concentration of the serum IL-21 of patients with CHB.
languagechi
sourceChina Online Journals (Wanfang)
vertitleThe dynamic changes and signification of IL-21 in the optimally treated chronic hepatitis B patients with poor response to nucleos(t)ide analogue drugs
ispartof中华实验和临床感染病杂志(电子版), 2016, Vol.10(2), pp.140-145
links
openurl$$Topenurl_article
backlink
0$$Uhttp://d.wanfangdata.com.cn/Periodical_zhsyhlcgrbzz201602003.aspx$$EView_this record_in_Wanfang_(CHINA)
1$$Uhttp://d.g.wanfangdata.com.hk/Periodical_zhsyhlcgrbzz201602003.aspx$$EView_this record_in_Wanfang_(HONG_KONG)
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutWanfang.html$$EView_the_Wanfang_Copyright_Statement
search
creatorcontrib
0闫改勤
1纪世博
2刘顺爱
3欧蔚妮
4赵莹莹
5马艳华
6成军
7邢卉春
8Yan Gaiqin
9Ji Shibo
10Liu Shun ai
11Ou Weini
12Zhao Yingying
13Ma Yanhua
14Cheng Jun
15Xing Huichun
title核苷(酸)类药物应答不佳的慢性乙型肝炎患者优化治疗过程中血清IL-21的动态变化及意义
description
0目的:通过检测核苷(酸)类似物治疗应答不佳慢性乙型肝炎患者在优化治疗过程中血清IL-21表达水平,探讨血清IL-21水平的动态变化与患者对抗病毒应答的相关性。方法检测25例核苷(酸)类似物治疗应答不佳的慢性乙型肝炎患者在接受优化的核苷(酸)类似物抗病毒治疗基线、12周、24周、36周、52周、64周、76周、88周和104周的血清并检测IL-21水平、HBV DNA定量、HBsAg、HBsAb、HBeAg、HBeAb和肝功能等相关指标,分析这些指标的动态变化及其之间的相关性;另选取15例HBV携带者、15例健康志愿者做对照。结果核苷(酸)类似物治疗应答不佳的慢性乙型肝炎患者优化治疗基线血清IL-21水平与无症状携带者血清IL-21水平差异无统计学意义,但均显著高于健康对照组(P =0.000、0.003);核苷(酸)类似物应答不佳的慢性乙型肝炎患者在优化治疗过程中血清HBV DNA、HBsAg、HBeAg、HBeAb均呈下降趋势,且HBV DNA水平及HBsAg浓度于治疗12周内下降速度最快,HBsAg浓度降低速度随治疗时间延长逐渐减慢。基线IL-21水平与优化治疗12~24周时的病毒量变化对数值存在中等强度的负相关性(r =-0.55、P =0.015),36周时IL-21水平与36~52周病毒量变化存在中等强度的负相关性(r =-0.62、P =0.001)。核苷(酸)类药物优化治疗过程中患者血清IL-21浓度呈现先升高后下降的趋势,峰值浓度在36周,为66.41 pg/ml,显著高于基线IL-21浓度(P =0.001),治疗至88周及104周时患者血清IL-21水平恢复到基线状态。结论乙型肝炎病毒感染的患者血清IL-21浓度升高,优化核苷(酸)类抗病毒治疗后,慢性乙型肝炎患者血清IL-21水平呈现一过性升高,峰值与HBV DNA的抑制及HBsAg、HBeAg等变化有一定的相关性。
1Objective To investigate of the levels of serum interleukin-21 (IL-21) in the optimally treated chronic hepatitis B (CHB) patients with poor response to nucleos(t)ide analogue drugs to investigate the relationship between the the serum IL-21 levels, the dynamic changes and patients’ viral response to antiviral therapy. Methods The serum of a total of 25 CHB patients with a poor response to nucleos(t) ide analogue antiviral therapy was detached before and after optimally treated for 12, 24, 36, 52, 64, 76, 88 and 104 weeks, and the levels of IL-21, HBsAg, HBsAb, HBeAg, HBeAb, HBV DNA load and the liver function were dedected, respectively. And then the dynamic changes of these indicators and the correlation were analyzed. Fifteen cases of hepatitis B virus carriers and 15 cases of healthy volunteers were selected as controls. Results There was no significant differences between the levels of the baseline IL-21 of the chronic hepatitis B patients poorly respond to nucleos(t)ide analogue antiviral therapy and the hepatitis B virus carriers, but they all significantly higher than the level of serum IL-21 concentration of the healthy people (P < 0.05). During the optimal therapy of the chronic hepatitis B patients poorly respond to nucleos(t) ide analogue antiviral therapy, the level of the serum HBV DNA, HBsAg, HBeAg and HBeAb all declined, and a rapid decline of HBV DNA during the first 12 weeks of treatment was observed, and the pace of the reduction of HBsAg slowed down with time. There was a moderate negative correlation between the IL-21 concentration of baseline and the logarithmic change of HBV load from 12 weeks to 24 weeks after treatment (r =-0.55, P < 0.05). A moderate negative correlation between the IL-21 concentration at week 36 and the decline of HBV load from week 36 to week 52 was also obversed (r =-0.62, P < 0.01). And the levels of IL-21 of the patients with CHB during treatment with nucleos(t)ide analogues increased at first and then declined and the peak concentration was 66.41 pg/ml, which came around at week 36 and was significantly higher than the baseline (P < 0.05), but at the 88th week and 104th week, the IL-21 declined to the levels that showed no significant differences compared with the baseline. Conclusions The levels of serum IL-21 increased in the patients with HBV infection, and after the optimal antiviral treatment with nucleos(t)ide analogue drugs, the levels of serum IL-21 of patients with CHB increased transiently, and some relevance were observed between the supression of HBV DNA, as well as the changes of the HBsAg, HBeAg and the peek concentration of the serum IL-21 of patients with CHB.
subject
0肝炎病毒,乙型
1肝炎,乙型,慢性
2白细胞介素21
3Hepatitis B Virus
4Chronic Hepatitis B
5Interleukin-21
general
0Chinese
1China Online Journals (Wanfang)
2国家科技重大专项课题项目(No.2014ZX10005001);国家自然科学基金项目(No.81201160);北京市中医药科技项目(No. JJ2014-25);国家“十二五”传染病重大专项(2012ZX10002003)
310.3877/cma.j.issn.1674-1358.2016.02.003
sourceidwanfang_jour
recordidwanfang_jourzhsyhlcgrbzz201602003
issn
01674-1358
116741358
rsrctypearticle
creationdate2016
searchscopewanfang_jour
scopewanfang_jour
alttitleThe dynamic changes and signification of IL-21 in the optimally treated chronic hepatitis B patients with poor response to nucleos(t)ide analogue drugs
startdate20160101
enddate20161231
addtitle中华实验和临床感染病杂志(电子版)
citationpf 140 pt 145 vol 10 issue 2
sort
title核苷(酸)类药物应答不佳的慢性乙型肝炎患者优化治疗过程中血清IL-21的动态变化及意义
author闫改勤 ; 纪世博 ; 刘顺爱 ; 欧蔚妮 ; 赵莹莹 ; 马艳华 ; 成军 ; 邢卉春
creationdate20160000
lso0120160000
facets
frbrgroupid7544009489638118154
frbrtype6
newrecords20170928
languagechi
creationdate2016
topic
0肝炎病毒,乙型
1肝炎,乙型,慢性
2白细胞介素21
3Hepatitis B Virus
4Chronic Hepatitis B
5Interleukin-21
collectionChina Online Journals (Wanfang)
prefilterarticles
rsrctypearticles
creatorcontrib
0闫改勤
1纪世博
2刘顺爱
3欧蔚妮
4赵莹莹
5马艳华
6成军
7邢卉春
8Yan Gaiqin
9Ji Shibo
10Liu Shun ai
11Ou Weini
12Zhao Yingying
13Ma Yanhua
14Cheng Jun
15Xing Huichun
jtitle中华实验和临床感染病杂志(电子版)
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0闫改勤
1纪世博
2刘顺爱
3欧蔚妮
4赵莹莹
5马艳华
6成军
7邢卉春
8Yan Gaiqin
9Ji Shibo
10Liu Shun ai
11Ou Weini
12Zhao Yingying
13Ma Yanhua
14Cheng Jun
15Xing Huichun
atitle核苷(酸)类药物应答不佳的慢性乙型肝炎患者优化治疗过程中血清IL-21的动态变化及意义
jtitle中华实验和临床感染病杂志(电子版)
date2016
risdate2016
volume10
issue2
spage140
epage145
pages140-145
issn1674-1358
formatjournal
genrearticle
ristypeJOUR
abstract
0目的:通过检测核苷(酸)类似物治疗应答不佳慢性乙型肝炎患者在优化治疗过程中血清IL-21表达水平,探讨血清IL-21水平的动态变化与患者对抗病毒应答的相关性。方法检测25例核苷(酸)类似物治疗应答不佳的慢性乙型肝炎患者在接受优化的核苷(酸)类似物抗病毒治疗基线、12周、24周、36周、52周、64周、76周、88周和104周的血清并检测IL-21水平、HBV DNA定量、HBsAg、HBsAb、HBeAg、HBeAb和肝功能等相关指标,分析这些指标的动态变化及其之间的相关性;另选取15例HBV携带者、15例健康志愿者做对照。结果核苷(酸)类似物治疗应答不佳的慢性乙型肝炎患者优化治疗基线血清IL-21水平与无症状携带者血清IL-21水平差异无统计学意义,但均显著高于健康对照组(P =0.000、0.003);核苷(酸)类似物应答不佳的慢性乙型肝炎患者在优化治疗过程中血清HBV DNA、HBsAg、HBeAg、HBeAb均呈下降趋势,且HBV DNA水平及HBsAg浓度于治疗12周内下降速度最快,HBsAg浓度降低速度随治疗时间延长逐渐减慢。基线IL-21水平与优化治疗12~24周时的病毒量变化对数值存在中等强度的负相关性(r =-0.55、P =0.015),36周时IL-21水平与36~52周病毒量变化存在中等强度的负相关性(r =-0.62、P =0.001)。核苷(酸)类药物优化治疗过程中患者血清IL-21浓度呈现先升高后下降的趋势,峰值浓度在36周,为66.41 pg/ml,显著高于基线IL-21浓度(P =0.001),治疗至88周及104周时患者血清IL-21水平恢复到基线状态。结论乙型肝炎病毒感染的患者血清IL-21浓度升高,优化核苷(酸)类抗病毒治疗后,慢性乙型肝炎患者血清IL-21水平呈现一过性升高,峰值与HBV DNA的抑制及HBsAg、HBeAg等变化有一定的相关性。
1Objective To investigate of the levels of serum interleukin-21 (IL-21) in the optimally treated chronic hepatitis B (CHB) patients with poor response to nucleos(t)ide analogue drugs to investigate the relationship between the the serum IL-21 levels, the dynamic changes and patients’ viral response to antiviral therapy. Methods The serum of a total of 25 CHB patients with a poor response to nucleos(t) ide analogue antiviral therapy was detached before and after optimally treated for 12, 24, 36, 52, 64, 76, 88 and 104 weeks, and the levels of IL-21, HBsAg, HBsAb, HBeAg, HBeAb, HBV DNA load and the liver function were dedected, respectively. And then the dynamic changes of these indicators and the correlation were analyzed. Fifteen cases of hepatitis B virus carriers and 15 cases of healthy volunteers were selected as controls. Results There was no significant differences between the levels of the baseline IL-21 of the chronic hepatitis B patients poorly respond to nucleos(t)ide analogue antiviral therapy and the hepatitis B virus carriers, but they all significantly higher than the level of serum IL-21 concentration of the healthy people (P < 0.05). During the optimal therapy of the chronic hepatitis B patients poorly respond to nucleos(t) ide analogue antiviral therapy, the level of the serum HBV DNA, HBsAg, HBeAg and HBeAb all declined, and a rapid decline of HBV DNA during the first 12 weeks of treatment was observed, and the pace of the reduction of HBsAg slowed down with time. There was a moderate negative correlation between the IL-21 concentration of baseline and the logarithmic change of HBV load from 12 weeks to 24 weeks after treatment (r =-0.55, P < 0.05). A moderate negative correlation between the IL-21 concentration at week 36 and the decline of HBV load from week 36 to week 52 was also obversed (r =-0.62, P < 0.01). And the levels of IL-21 of the patients with CHB during treatment with nucleos(t)ide analogues increased at first and then declined and the peak concentration was 66.41 pg/ml, which came around at week 36 and was significantly higher than the baseline (P < 0.05), but at the 88th week and 104th week, the IL-21 declined to the levels that showed no significant differences compared with the baseline. Conclusions The levels of serum IL-21 increased in the patients with HBV infection, and after the optimal antiviral treatment with nucleos(t)ide analogue drugs, the levels of serum IL-21 of patients with CHB increased transiently, and some relevance were observed between the supression of HBV DNA, as well as the changes of the HBsAg, HBeAg and the peek concentration of the serum IL-21 of patients with CHB.
doi10.3877/cma.j.issn.1674-1358.2016.02.003